Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | TOP2A | P11388 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29864668 | 0.89 | IDO1 (0.44) | IDO1TOP2ALMNAALDH1A1MAPT | |
| SCHEMBL25074716 | 0.89 | IDO1 (0.44) | IDO1TOP2ALMNAALDH1A1MAPT | |
| SCHEMBL29864563 | 0.81 | ALDH1A1 (0.43) | IDO1TOP2ALMNAALDH1A1MAPT | |
| SCHEMBL25074786 | 0.81 | ALDH1A1 (0.43) | IDO1TOP2ALMNAALDH1A1MAPT | |
| SCHEMBL25208697 | 0.81 | ALDH1A1 (0.45) | IDO1ALDH1A1MAPTKDM4EHSD17B10 | |
| SCHEMBL6676039 | 0.80 | RAD52 (0.48) | IDO1ALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL5450923 | 0.80 | IDO1 (0.46) | IDO1TOP2AALDH1A1MAPTKDM4E | |
| SCHEMBL25074823 | 0.80 | TOP2A (0.41) | TOP2AALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL6679158 | 0.79 | KCNH3 (0.48) | IDO1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL5452905 | 0.79 | CA1 (0.50) | TOP2ALMNAALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | disclosed |
| WO-2004026846-A1 | DNA-TARGETED BENZOTRIAZINE 1,4-DIOXIDES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | HIF1AN, HIF1A, HYOU1 | IDO1 924/4885TOP2A 4/4885LMNA 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.